Immune system cells can be engineered outside of the body in a type of therapy called CAR-T. Now, Johns Hopkins scientists are developing ways to sidestep such cell manufacturing with a biodegradable ...

Johns Hopkins Medicine scientists say they have developed a simplified version of biodegradable nanoparticles that can "educate" the immune system to find and destroy disease-causing cells throughout ...

Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically ...

The design of synthetic developmental programs for multicellular mammalian systems is a cornerstone of synthetic biology. The programs hinge on the construction of gene regulatory circuits that ...

FACE binds to CD71 on the T‑cell surface in CAR T cell preparation, and post-infusion, the same FACE molecules attach to CD71 on leukemia cells.

To prevent viruses from infecting cells, our immune systems depend on antibodies. Antibodies bind specific antigens present on viruses to tag them for destruction. For some antibodies, known as ...

With cutting-edge technology, a robust regulatory framework, and a highly skilled team, BTCF is committed to driving innovation in cell therapy research and clinical translation, helping to bring next ...

Proteomics-informed, genome-edited CHO design increased productivity up to three-fold and titers two-fold, strengthening CLD for novel biologics and biosimilars. Extended culture robustness was ...

Blow up a long balloon and two things happen: it gets longer and it gets wider. Now imagine a living cell that inflates itself under enormous pressure and yet only grows longer, never adding width.